TCV Trust & Wealth Management Inc. Sells 217 Shares of Becton, Dickinson and Company (NYSE:BDX)

TCV Trust & Wealth Management Inc. lessened its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,096 shares of the medical instruments supplier’s stock after selling 217 shares during the period. TCV Trust & Wealth Management Inc.’s holdings in Becton, Dickinson and Company were worth $476,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in BDX. Brighton Jones LLC increased its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB grew its stake in Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after buying an additional 20,859 shares in the last quarter. Arete Wealth Advisors LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter valued at $767,000. Busey Bank lifted its position in shares of Becton, Dickinson and Company by 3.8% during the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock worth $15,031,000 after acquiring an additional 2,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Becton, Dickinson and Company by 79.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 4,483 shares of the stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the transaction, the executive vice president now owns 24,345 shares in the company, valued at $5,380,488.45. The trade was a 15.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 9,844 shares of company stock worth $2,210,716. 0.36% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $229.50 on Wednesday. The stock has a market cap of $66.56 billion, a price-to-earnings ratio of 38.12, a PEG ratio of 1.65 and a beta of 0.40. The company has a quick ratio of 0.74, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. The business has a 50-day simple moving average of $232.20 and a 200 day simple moving average of $233.99. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. On average, research analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a stock buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BDX. Piper Sandler increased their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.